(Q47916199)

English

Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study

scientific article published on 10 April 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/22494956

Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/22494956

multiple sclerosis

0 references

0 references

1 reference

based on heuristic

inferred from title

9

object named as

Ludwig Kappos

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

0 references

author name string

Virginia Devonshire

1

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/22494956

Eva Havrdova

2

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/22494956

Ernst Wilhelm Radue

3

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/22494956

Paul O'Connor

4

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/22494956

Lixin Zhang-Auberson

5

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/22494956

Catherine Agoropoulou

6

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/22494956

Dieter Adrian Häring

7

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/22494956

Gordon Francis

8

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/22494956

FREEDOMS study group

10

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/22494956

publication date

10 April 2012

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/22494956

Lancet Neurology

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/22494956

11

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/22494956

5

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/22494956

420-428

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/22494956

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970056-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970056-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970056-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral fingolimod (FTY720) for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970056-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-Term Adherence to Interferon β Therapy in Relapsing-Remitting Multiple Sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970056-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Glatiramer acetate in treatment-naïve and prior interferon-beta-1b-treated multiple sclerosis patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970056-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970056-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Statistical methods for the analysis of relapse data in MS clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970056-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Statistics in medicine--reporting of subgroup analyses in clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970056-X

7 January 2021

based on heuristic

inferred from DOI database lookup

No adjustments are needed for multiple comparisons

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970056-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970056-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970056-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Relapses in multiple sclerosis are age- and time-dependent

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970056-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970056-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Gender effects on intramuscular interferon beta-1a in relapsing-remitting multiple sclerosis: analysis of 1406 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970056-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1474-4422(12)70056-X

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/22494956

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/22494956

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47916199&oldid=2175694268"